# EDGAR Filing Document

**Accession Number:** 0001771885
**File Stem:** 0002072045-25-000004
**Filing Date:** 2025-6
**Character Count:** 11704
**Document Hash:** 0f0b14d6ab0c34ac5f0c61b17d5daca6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002072045-25-000004.hdr.sgml**: 20250623

**ACCESSION NUMBER**: 0002072045-25-000004

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250623

**DATE AS OF CHANGE**: 20250623

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Quantum Biopharma Ltd.
- **CENTRAL INDEX KEY:** 0001771885
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91661
- **FILM NUMBER:** 251063588

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 55 UNIVERSITY AVENUE, SUITE 1003
- **CITY:** TORONTO
- **PROVINCE COUNTRY:** A6
- **ZIP:** M5J 2H7
- **BUSINESS PHONE:** (416) 854-8884

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 55 UNIVERSITY AVENUE, SUITE 1003
- **CITY:** TORONTO
- **PROVINCE COUNTRY:** A6
- **ZIP:** M5J 2H7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FSD Pharma Inc.
- **DATE OF NAME CHANGE:** 20190327
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Malone Wealth Ventures LLC
- **CENTRAL INDEX KEY:** 0002072045

**ORGANIZATION NAME:**
- **EIN:** 861544286
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 9201 W STATE ST. STE 126
- **CITY:** BOISE
- **STATE:** ID
- **ZIP:** 83714
- **BUSINESS PHONE:** 2089854526

**MAIL ADDRESS:**
- **STREET 1:** 9201 W STATE ST. STE 126
- **CITY:** BOISE
- **STATE:** ID
- **ZIP:** 83714

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Quantum Biopharma Ltd.**

*(Name of Issuer)*

**Common Stock**

*(Title of Class of Securities)*

**74764Y205**

*(CUSIP Number)*

**Malone Wealth Ventures**<br>9201 W State St. Ste 126<br>Boise ID 83714<br>2089854526

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/12/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **74764Y205** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Malone Wealth Ventures LLC** | Name of reporting person<br>**Malone Wealth Ventures LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**—** | Source of funds (See Instructions)<br>**—** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**IDAHO** | Citizenship or place of organization<br>**IDAHO** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**52265.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**580806.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**580806.00** | Aggregate amount beneficially owned by each reporting person<br>**580806.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | |
| 13 | Percent of class represented by amount in Row (11)<br>**17.0%** | Percent of class represented by amount in Row (11)<br>**17.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IA** | Type of Reporting Person (See Instructions)<br>**IA** | |

---

**Comment for Reporting Person:** Les Gro

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock

**(b) Name of Issuer:**
Quantum Biopharma Ltd.

**(c) Address of Issuer's Principal Executive Offices:**
55 UNIVERSITY AVENUE, SUITE 1003, 55 UNIVERSITY AVENUE, SUITE 1003, TORONTO, A6, M5J 2H7

Les Gro

**Item 4. Purpose of Transaction**

The securities were acquired for investment purposes. Kevin Malone serves as Advisor to the Board of Directors of the issuer and may, in such capacity, participate in discussions relating to strategic direction, financing, capitalization, or corporate governance. As such, the Reporting Persons may be deemed to have an intent to influence the control of the issuer.

The Reporting Persons may, from time to time, acquire additional securities of the issuer or dispose of some or all of the securities reported herein, depending on market conditions, investment strategies, or other factors. Except as set forth herein, the Reporting Persons do not currently have any plans or proposals which relate to or would result in any of the actions enumerated in paragraphs (a) through (j) of Item 4.

**Item 5. Interest in Securities of the Issuer**

**(a)**
580,806 and 17%

**(b)**
52,265

**(c)**
The following transactions in the Common Stock of the issuer were effected by Malone Wealth Ventures LLC on behalf of advisory clients during the 60 days preceding the filing of this Schedule 13D/A. All transactions were open market purchases executed on public exchanges:

    June 13, 2025 - Purchased 1,000 shares at $19.10 per share

    June 13, 2025 - Purchased 10 shares at $19.25 per share

    June 13, 2025 - Purchased 100 shares at $18.80 per share

    June 13, 2025 - Purchased 24 shares at $19.11 per share

    June 13, 2025 - Purchased 1,000 shares at $19.83 per share

    June 13, 2025 - Purchased 1,000 shares at $21.10 per share

    June 13, 2025 - Purchased 250 shares at $20.65 per share

    June 13, 2025 - Purchased 1,000 shares at $20.65 per share

    June 13, 2025 - Purchased 1,000 shares at $20.55 per share

    June 13, 2025 - Purchased 1,000 shares at $20.40 per share

    June 13, 2025 - Purchased 1,000 shares at $20.92 per share

    June 13, 2025 - Purchased 200 shares at $20.70 per share

    June 13, 2025 - Purchased 50 shares at $20.70 per share

    June 13, 2025 - Purchased 25 shares at $20.70 per share

    June 13, 2025 - Purchased 1,000 shares at $20.70 per share

    June 13, 2025 - Purchased 40 shares at $20.70 per share

    June 13, 2025 - Purchased 30 shares at $20.70 per share

    June 13, 2025 - Purchased 40 shares at $20.70 per share

    June 13, 2025 - Purchased 1,000 shares at $20.40 per share

    June 13, 2025 - Purchased 1,000 shares at $20.30 per share

    June 13, 2025 - Purchased 1,000 shares at $20.08 per share

    June 13, 2025 - Purchased 1,000 shares at $19.30 per share

    June 13, 2025 - Purchased 1,000 shares at $19.40 per share

    June 13, 2025 - Purchased 1,000 shares at $19.30 per share

    June 13, 2025 - Purchased 5,000 shares at $19.70 per share

    June 16, 2025 - Purchased 1,000 shares at $21.02 per share

    June 16, 2025 - Purchased 50 shares at $21.02 per share

    June 16, 2025 - Purchased 100 shares at $21.02 per share

    June 16, 2025 - Purchased 80 shares at $21.02 per share

    June 16, 2025 - Purchased 30 shares at $21.02 per share

    June 16, 2025 - Purchased 200 shares at $21.02 per share

    June 16, 2025 - Purchased 200 shares at $21.02 per share

    June 16, 2025 - Purchased 50 shares at $21.02 per share

    June 16, 2025 - Purchased 1,000 shares at $21.57 per share

    June 16, 2025 - Purchased 1,000 shares at $21.26 per share

    June 16, 2025 - Purchased 100 shares at $21.58 per share

    June 17, 2025 - Purchased 1,000 shares at $26.19 per share

    June 17, 2025 - Purchased 1,000 shares at $24.90 per share

    June 17, 2025 - Purchased 1,000 shares at $24.00 per share

    June 17, 2025 - Purchased 2 shares at $25.02 per share

    June 17, 2025 - Purchased 50 shares at $25.06 per share

    June 17, 2025 - Purchased 400 shares at $25.06 per share

    June 17, 2025 - Purchased 1,000 shares at $25.06 per share

    June 17, 2025 - Purchased 12 shares at $25.02 per share

    June 17, 2025 - Purchased 50 shares at $25.02 per share

    June 17, 2025 - Purchased 15 shares at $25.06 per share

    June 17, 2025 - Purchased 100 shares at $25.02 per share

    June 17, 2025 - Purchased 11 shares at $25.00 per share

    June 17, 2025 - Purchased 40 shares at $25.02 per share

    June 17, 2025 - Purchased 200 shares at $25.06 per share

    June 17, 2025 - Purchased 400 shares at $25.06 per share

    June 17, 2025 - Purchased 190 shares at $25.06 per share

    June 17, 2025 - Purchased 25 shares at $25.06 per share

    June 17, 2025 - Purchased 110 shares at $25.06 per share

    June 17, 2025 - Purchased 15 shares at $25.02 per share

    June 17, 2025 - Purchased 20 shares at $25.02 per share

    June 17, 2025 - Purchased 40 shares at $25.06 per share

    June 17, 2025 - Purchased 1,000 shares at $25.50 per share

    June 18, 2025 - Purchased 100 shares at $27.00 per share

    June 18, 2025 - Purchased 1,000 shares at $27.95 per share

    June 18, 2025 - Purchased 1,000 shares at $29.17 per share

    June 18, 2025 - Purchased 1,000 shares at $30.80 per share

    June 18, 2025 - Purchased 1,000 shares at $31.00 per share

    June 18, 2025 - Purchased 1,000 shares at $31.31 per share

    June 18, 2025 - Purchased 119 shares at $30.88 per share

    June 18, 2025 - Purchased 1,000 shares at $30.24 per share

    June 18, 2025 - Purchased 20 shares at $31.20 per share

    June 20, 2025 - Purchased 1,000 shares at $36.71 per share

    June 20, 2025 - Purchased 1,000 shares at $37.55 per share

    June 20, 2025 - Purchased 1,000 shares at $37.50 per share

    June 20, 2025 - Purchased 1,000 shares at $37.35 per share

    June 20, 2025 - Purchased 1,000 shares at $36.26 per share

    June 20, 2025 - Purchased 1,000 shares at $37.59 per share

    June 20, 2025 - Purchased 1,000 shares at $35.30 per share

All trades were executed by Malone Wealth Ventures LLC and were directed all at client's requests.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Pursuant to an agreement with the issuer, Quantum Biopharma Inc., Kevin Malone serves as an advisor to the Board of Directors. In connection with this engagement, the Reporting Person received a grant of 30,000 restricted stock units (RSUs), with additional RSUs issuable upon the achievement of certain goals.

The Reporting Person disclaims beneficial ownership of the unvested RSUs except to the extent that such rights are vested or become exercisable within 60 days of the date of this filing.

Other than as described herein, there are no contracts, arrangements, understandings, or relationships (legal or otherwise) between the Reporting Persons and any other person with respect to any securities of the issuer.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Malone Wealth Ventures LLC

**Signature:** Kevin M Malone

**Name/Title:** President and CEO

**Date:** 06/23/2025